Remove 2030 Remove Immunization Remove Vaccines
article thumbnail

mRNA licensing agreements rise 800% in value as confidence grows beyond vaccines

Express Pharma

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. billion in 2030. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104
article thumbnail

WHO prequalifies meningitis conjugate vaccine

European Pharmaceutical Review

The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First COVID-19 impact report on global vaccine markets

European Pharmaceutical Review

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

article thumbnail

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. for serogroup W to 20.5

article thumbnail

Vaccines Europe launches first pipeline review

European Pharmaceutical Review

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.

article thumbnail

SII likely front-runner to win supply of HPV vaccines for Universal Immunisation Program: GlobalData

Express Pharma

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. million in 2030. per cent from 0.43

article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. During the American Society of Clinical Oncology (ASCO) 2023 annual meeting, BioNTech revealed promising Phase I results for the pancreatic cancer drug BNT122 combined with the immune checkpoint inhibitor (ICI) atezolizumab.

Immunity 110